Day 3Wednesday, 19 March 2025

Location: Exhibit hall stage

Skape Bio is a biotechnology company harnessing AI-powered protein design and synthetic biology to generate novel functional "Novobody" modulators of integral membrane proteins.

Our cutting-edge computational platform integrates deep evolutionary insights with advanced protein design methodologies tailored specifically for integral membrane proteins, generating molecules with exceptional developability and function. Our proprietary experimental platform enables high-throughput screening directly in human cells, bypassing the need for target solubilization and unlocking previously inaccessible GPCRs. This approach has demonstrated broad applicability across GPCR families, successfully delivering novel agonists and antagonists.

Through de novo design, Novobodies achieve precise control over target binding and possess biophysical properties that enable superior pharmacology, such as gut stability, potency, and selectivity, while offering a simpler manufacturing process compared to traditional antibodies. Skape Bio's in-cell screening platform evaluates tens of thousands of Novobody designs in their natural cellular context, accelerating target-directed discovery and optimization for first- and best-in-class indications in oncology, inflammation, metabolic disease, and neurology. Our robust platform infrastructure also supports future active learning for improved AI-driven Novobody design.

In addition to its in-house discovery programs, Skape Bio actively seeks partnerships with leading pharmaceutical companies to co-develop novel therapeutics and unique tool compounds.

Skape Bio is headquartered in Copenhagen, Denmark, a spinout from the three-year "Modulate" collaboration between the BioInnovation Institute and the University of Washington's Institute for Protein Design (IPD), founded and led by David Baker, recipient of the 2024 Nobel Prize in Chemistry.

Location: Exhibit hall stage

InSilicoTrials is a leading technology company revolutionizing drug development through AI-powered simulation. Our platform provides pharmaceutical and biotech companies with access to a vast library of computational models, enabling them to simulate drug interactions, predict outcomes, and accelerate the discovery of new treatments. By leveraging digital patient twins and advanced AI algorithms, we offer a more efficient and cost-effective approach to drug development, reducing the need for early-stage human trials and improving decision-making throughout the process.

Location: Exhibit hall stage

Menten AI is developing generative AI to design cyclic peptide therapeutics for challenging drug targets beyond the reach of small molecules and biologics. Its proprietary platform is capable of designing potent macrocycles with desirable drug properties including oral bioavailability and cell-permeability. The team has shown in vitro and in vivo validation of their platform for complex drug targets including challenging protein-protein interfaces (PPIs). The company has partnerships with top-10 pharma (e.g. Bristol Myers Squibb) to accelerate their preclinical drug discovery efforts. Menten AI is backed by top VCs including Social Impact Capital, Uncork Capital, Khosla Ventures, and Y-Combinator.

Location: Exhibit Hall Stage

Amaro is a therapeutic platform company focused on the emerging field of chemosensory receptors, specifically the TAS2R family, as therapeutic targets. The TAS2R family, more commonly known as bitter taste receptors, are G Protein-Coupled Receptors (GPCRs). These receptors are not confined to the oral cavity but ubiquitously expressed - every tissue expresses bitter taste receptors. In addition, TAS2R receptors are expressed on and in certain cells including cancer, immune and senescent cells. Despite being GPCRs, only recently has there been strong evidence of their potential as therapeutic targets. Our position is that bitterants are a necessary and fundamental nutrient to human health and that therapeutics, supplements, nutraceuticals, and functional foods designed to activate these receptors can provide significant benefit to patients and consumers across a spectrum of chronic diseases and conditions, e.g., obesity (activation of GLP-1 and CCK), diabetes, polycystic ovary syndrome (PCOS), inflammation, aging (clearance of senescent cells), etc. Further, it is likely that taste receptors - much like olfactory receptors - act in a concerted manner to tailor the body's immune and metabolic response to certain ligands (e.g., bitter compounds), in a systems-like manner. Amaro is at the forefront of this therapeutic sector and is establishing the preeminent discovery platform to exploit the bitter taste receptor system for the treatment of human diseases and conditions. The company is seeking Seed, possibly Series A, funding to advance the company's platform and preclinical program(s).

Location: Exhibit hall stage

Biorevert Inc. was found with proven records of scientific achievements in cancer and drug discovery platform to identify first-in-class targets and their relative mechanism of actions through computational simulation and analysis. We currently have several pipelines in colon, lung, and liver cancers for developing as small molecule (hit) and gene therapies (hit-to-lead) that can revert cancer cells into normal-functioning cells.

Location: Exhibit hall stage

HD Immune GmbH (HDI), a privately owned company based in Vienna/Austria focused on the treatment of Huntington's disease using a passive antibody to remove mutant Huntingtin protein (HTT), which is the cause and driver of this fatal disorder. HDI has developed a human antibody that binds in the pM range to HTT, which is undergoing in vitro, in vivo and ex vivo pre-clinical characterization. The company was founded by Stefan Bartl (CEO,CSO) and Lionel Wightman (COO, CFO) in 2023.

Location: Exhibit hall stage

OncoBone Therapeutics develops novel therapies for cancer patients with bone metastases utilising our novel innovative osteoimmuno-oncology (OIO)© concept. We identify potential OIO drug candidates from partners and confirm their preclinical efficacy for bone metastases in "early killer experiments" in our Bone Metastasis Technology Platform (BMTP)©. IND-enabling studies will be performed to effective assets that will be outlicensed to larger pharma/biotech companies for clinical development.

Location: Exhibit hall stage

Mitodicure is the only biotech startup worldwide pursuing a curative approach for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), which is also the most serious sequel of Long COVID. ME/CFS is a disease with no effective treatment option. Driven by autoimmunity ME/CFS leads to severe muscular and mental fatigue, post-exertional malaise and other symptoms. Patients only have enough muscle energy to maintain bodily functions for simple survival. Disease severity scores are similar to MS. 25% of sufferers are in need of care, far more are unemployed. The prevalence of ME/CFS is 1.3% (according to the U.S. CDC) and is on the rise as post-acute infection syndrome due to COVID-19. This constitutes a large market of more than 6 million patients in the U.S., UK, France, Germany, Italy, Spain, and Japan alone with attractive peak sales estimates for our small molecule drug. ME/CFS is untapped by the biopharma industry because it was misclassified as a psychosomatic disorder, risky to target. However, recent investigations including electron microscopic findings show that mitochondrial damage and cell necrosis in skeletal muscle are the causes of fatigue and complaints. Mitodicure's oral tablet MDC002 heals these mitochondrial disturbances and, additionally, improves blood flow. With regard to preclinical proof-of-concept pharmacology, the German regulator BfArM considers our data to be sufficient to justify clinical trials in ME/CFS. Mitodicure is a young company, has completed its pre-seed financing in 2024, and is led by a very experienced biopharma team with translational expertise. We aim to have completed all IND-enabling studies in 18 months. In contrast to symptom-oriented off-label therapies, our innovative approach can favorably influence the course of ME/CFS for the first time. MDC002 also has potential in the indications Fibromyalgia, Lyme disease and Gulf War syndrome as well as in chronic fatigue associated with Ehlers-Danlos and Marfan syndromes.

Location: Exhibit hall stage

Symbiotica Therapeutics is a newborn biotech innovative start-up based in Italy. We developed a revolutionary delivery system that goes beyond genetic therapy or lipid nanoparticles systems, which are used in modern therapies. Our proprietary delivery system called symbiotic therapy, uses symbiotic particles injected under the host skin as a "tatoo" to continuously deliver over time a functionalized peptidic and/or proteic therapeutic agent to mediate: i) an hormonal signaling, ii) an intra-cellular or intra-nuclear function or iii) specific organ or cell populations delivery. Our delivery system showed impressive results during in vitro and in vivo experiments, allowing us to deposit a patent recently. As next step, we plan to run a pre-clinical trial in mice and non human primates in the next few years before to reach the clinical stage.

Location: Exhibit hall stage

KalphaTech, a Croatian deep-tech startup, is revolutionizing materials analysis by offering unprecedented speed, reliability, and predictive power. Our state-of-the-art structural analysis of small-drug molecules is built on decades of expertise in structural chemistry and solid-state characterization. Founded in 2023 by an interdisciplinary team of five PhDs, we leverage our experience in crystallography, data science, and machine learning to build our AI engine.

Partnered with leading Croatian research institutions, KalphaTech offers innovative services to early-drug discovery companies, CROs, and CDMOs, optimizing solid form analysis, polymorph, solubility, and stability screening. Our technology requires only milligrams of material to identify and structurally characterize various forms, including solvates and polymorphs, without the need for hardware upgrades.

KalphaTech accelerates drug development timelines and reduces risks and costs for our partners and clients by providing fast, accurate, and comprehensive materials analysis. Let us help you innovate.

Location: Exhibit hall stage

ProtOS is an AI-first protein design company developing therapeutics to treat undruggables. We generate AI proteins that allow us to go beyond the limits of small molecule drugs, harnessing nature's protein ingenuity - yet engineering it to perform novel functions. Our AI foundation models create therapeutic proteins that are safe and effective by design, creating a paradigm shift in drug development - from accidental discovery to intentional design.

Location: Exhibit Hall Stage

Break, breathe, and thrive!

Take a break from your busy schedule to recharge and rejuvenate by immersing yourself in moments of tranquility and self-care.

These sessions are designed to refresh your body and mind so you can get through a full conference day with more ease.

Open to all, without prerequisites.

Sustainability Focus Area: Social Responsibility

Visit to the District’s scientific anchors. Research Hospital Galeazzi-Sant'Ambrogio, internationally renowned for its top-ranked Orthopedics department (with presentations by Research Hospital San Raffaele and the national TT network PerfeTTO), followed by Human Technopole, Italy's state-of-the-art research center for Genomics, Neurogenomics, and Computational Biology.

This is a unique opportunity to engage with leading research institutions and companies, fostering strategic collaborations.

Advance sign-up is required to participate. Register now to secure your spot!

Meeting and networking with some of its leading companies: Zambon, AGC Biologics, Axxam, Champions Oncology and Sibylla.

This is a unique opportunity to engage with leading research institutions and companies, fostering strategic collaborations.

Advance sign-up is required to participate. Register now to secure your spot!